Amyotrophic Lateral Sclerosis Market Research Report - Forecast to 2027

筋萎縮性側索硬化症の市場調査レポート:タイプ別(家族性ALS)、治療別(投薬、理学療法、言語療法)、診断別(臨床検査、画像検査)、エンドユーザー(病院、専門センター)-2027年までの予測

ID: MRFR/Pharma/4366-CR | | Region: Global | 115 Pages         

1 Executive Summary

2 Market Introduction

2.1 Definition 17

2.2 Scope of the Study 17

2.3 List of Assumptions 17

2.4 Market Structure 18

3 Research Methodology

3.1 Research Process 20

3.2 Primary Research 21

3.3 Secondary Research 22

3.4 Market Size Estimation 23

3.5 Forecast Model 23

4 Market Dynamics

4.1 Overview 25

4.2 Drivers 26

4.2.1 Growing Incidence of Amyotrophic Lateral Sclerosis (ALS) 26

4.2.2 Rising Geriatric Population 26

4.2.3 Growing Awareness about Amyotrophic Lateral Sclerosis 26

4.3 Restraints 27

4.3.1 High Cost of ALS Treatment 27

4.4 Opportunities 27

4.4.1 Increasing Strategic Collaborations of Major Companies and Research Institutes for the Development of ALS Treatment 27

5 Market Factor Analysis

5.1 Porter’s Five Forces Model 29

5.1.1 Bargaining Power of Suppliers 30

5.1.2 Bargaining Power of Buyers 30

5.1.3 Threat of New Entrants 30

5.1.4 Threat of Substitutes 30

5.1.5 Intense Rivalry 30


5.2 Value Chain Analysis 31

5.2.1 Raw Material Sourcing 31

5.2.2 Manufacturing 31

5.2.3 Distribution & Sales 31

5.2.4 Post-Sales Monitoring 32

5.3 Investment Feasibility Analysis 32

5.4 Pricing Analysis 32

6 Global Amyotrophic Lateral Sclerosis Market, by Type

6.1 Overview 34

6.2 Sporadic ALS 34

6.3 Familial ALS 35

7 Global Amyotrophic Lateral Sclerosis Market, by Treatment

7.1 Overview 37

7.2 Medication 38

7.3 Physical Therapy 39

7.4 Respiratory Therapy 39

7.5 Speech Therapy 40

7.6 Others 40

8 Global Amyotrophic Lateral Sclerosis Market, by End User

8.1 Overview 42

8.2 Hospitals 42

8.3 Specialty Centers 43

8.4 Research and Academic Institutes 44

8.5 Others 44

9 Global Amyotrophic Lateral Sclerosis Market, by Region

9.1 Overview 46

9.2 Americas 47

9.2.1 North America 49

9.2.1.1 US 51

9.2.1.2 Canada 53

9.2.2 Latin America 54

9.3 Europe 56

9.3.1 Western Europe 58

9.3.1.1 Germany 61

9.3.1.2 France 62

9.3.1.3 UK 64

9.3.1.4 Italy 65

9.3.1.5 Spain 67

9.3.1.6 Rest of Western Europe 68

9.3.2 Eastern Europe 70

9.4 Asia-Pacific 72

9.4.1 Japan 74

9.4.2 Australia 76

9.4.3 China 77

9.4.4 India 79

9.4.5 South Korea 80

9.4.6 Rest of Asia-Pacific 82

9.5 Middle East & Africa 84

9.5.1 Middle East 86

9.5.2 Africa 88

10 Company Landscape

10.1 Overview 91

10.2 Company Ranking 91

11 Company Profile

11.1 Ascend Laboratories LLC 94

11.1.1 Company Overview 94

11.1.2 Financial Overview 94

11.1.3 Products/Services Offered 94

11.1.4 SWOT Analysis 95

11.1.5 Key Developments 95

11.1.6 Key Strategy 95

11.2 Apotex Inc. 96

11.2.1 Company Overview 96

11.2.2 Financial Overview 96

11.2.3 Products/Services Offered 96

11.2.4 SWOT Analysis 96

11.2.5 Key Developments 96

11.2.6 Key strategy 96


11.3 Biogen 97

11.3.1 Company Overview 97

11.3.2 Financial Overview 97

11.3.3 Products/Services Offered 98

11.3.4 SWOT Analysis 98

11.3.5 Key Developments 98

11.3.6 Key strategy 98

11.4 Covis Pharma 99

11.4.1 Company Overview 99

11.4.2 Financial Overview 99

11.4.3 Products/Services Offered 99

11.4.4 SWOT Analysis 100

11.4.5 Key Developments 100

11.4.6 Key Strategy 100

11.5 Ionis Pharmaceuticals 101

11.5.1 Company Overview 101

11.5.2 Financial Overview 101

11.5.3 Products/Services Offered 101

11.5.4 SWOT Analysis 102

11.5.5 Key Developments 102

11.5.6 Key Strategy 102

11.6 ITF Pharma 103

11.6.1 Company Overview 103

11.6.2 Financial Overview 103

11.6.3 Products/Services Offered 103

11.6.4 Key Developments 103

11.6.5 SWOT Analysis 103

11.6.6 Key Strategy 103

11.7 Mitsubishi Tanabe Pharma America 104

11.7.1 Company Overview 104

11.7.2 Financial Overview 104

11.7.3 Products/Services Offered 105

11.7.4 SWOT Analysis 105

11.7.5 Key Developments 105

11.7.6 Key strategy 105

11.8 Mylan N.V. 106

11.8.1 Company Overview 106

11.8.2 Financial Overview 106

11.8.3 Products/Services Offered 107

11.8.4 SWOT Analysis 107

11.8.5 Key Developments 107

11.8.6 Key Strategy 107

11.9 Sanofi 108

11.9.1 Company Overview 108

11.9.2 Financial Overview 108

11.9.3 Products/Services Offered 108

11.9.4 SWOT Analysis 109

11.9.5 Key Developments 109

11.9.6 Key Strategy 109

11.10 Sun Pharmaceutical Industries Ltd 110

11.10.1 Company Overview 110

11.10.2 Financial Overview 110

11.10.3 Products/Services Offered 110

11.10.4 SWOT Analysis 111

11.10.5 Key Development 111

11.10.6 Key Strategy 111

12 Appendix

12.1 Discussion Blue Print 113

13 List of Tables

TABLE 1 MARKET SYNOPSIS 15

TABLE 2 LIST OF ASSUMPTIONS 17

TABLE 3 GLOBAL ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 34

TABLE 4 GLOBAL ALS MARKET FOR SPORADIC ALS, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 5 GLOBAL ALS MARKET FOR FAMILIAL ALS, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 6 GLOBAL ALS MARKET FOR TREATMENT, 2020–2027 (USD MILLION) 37

TABLE 7 GLOBAL ALS MARKET FOR MEDICATION, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 8 GLOBAL ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL ALS MARKET FOR PHYSICAL THERAPY, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 10 GLOBAL ALS MARKET FOR RESPIRATORY THERAPY, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 11 GLOBAL ALS MARKET FOR SPEECH THERAPY, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 12 GLOBAL ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 42

TABLE 13 GLOBAL ALS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 14 GLOBAL ALS MARKET FOR SPECIALTY CENTERS, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 15 GLOBAL ALS MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 16 GLOBAL ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 17 AMERICAS: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 18 AMERICAS: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 19 AMERICAS: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 48

TABLE 20 AMERICAS: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 48

TABLE 21 AMERICAS: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

TABLE 22 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 49

TABLE 23 NORTH AMERICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

TABLE 24 NORTH AMERICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 50

TABLE 25 NORTH AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 50

TABLE 26 NORTH AMERICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 27 US: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 28 US: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52

TABLE 29 US: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 52

TABLE 30 US: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 31 CANADA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 32 CANADA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 53

TABLE 33 CANADA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 54

TABLE 34 CANADA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 54

TABLE 35 LATIN AMERICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 36 LATIN AMERICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 37 LATIN AMERICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 55

TABLE 38 LATIN AMERICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 55

TABLE 39 EUROPE: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 56

TABLE 40 EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 41 EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

TABLE 42 EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 57

TABLE 43 EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 58

TABLE 44 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59

TABLE 45 WESTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 46 WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 47 WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 60

TABLE 48 WESTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 49 GERMANY: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 50 GERMANY: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61

TABLE 51 GERMANY: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 62

TABLE 52 GERMANY: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 62

TABLE 53 FRANCE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 54 FRANCE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 63

TABLE 55 FRANCE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 63

TABLE 56 FRANCE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 57 UK: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 58 UK: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 64

TABLE 59 UK: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 65

TABLE 60 UK: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 65

TABLE 61 ITALY: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 62 ITALY: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 66

TABLE 63 ITALY: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 66

TABLE 64 ITALY: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 66

TABLE 65 SPAIN: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 66 SPAIN: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

TABLE 67 SPAIN: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 68

TABLE 68 SPAIN: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 68

TABLE 69 REST OF WESTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 70 REST OF WESTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 69

TABLE 71 REST OF WESTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 69

TABLE 72 REST OF WESTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 69

TABLE 73 EASTERN EUROPE: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 74 EASTERN EUROPE: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 70

TABLE 75 EASTERN EUROPE: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 71

TABLE 76 EASTERN EUROPE: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 77 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72

TABLE 78 ASIA-PACIFIC: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 79 ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 80 ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 73

TABLE 81 ASIA-PACIFIC: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 82 JAPAN: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 83 JAPAN: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75

TABLE 84 JAPAN: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 75

TABLE 85 JAPAN: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 86 AUSTRALIA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 87 AUSTRALIA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 76

TABLE 88 AUSTRALIA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 77

TABLE 89 AUSTRALIA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 77

TABLE 90 CHINA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 91 CHINA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 78

TABLE 92 CHINA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 78

TABLE 93 CHINA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 94 INDIA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 95 INDIA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 96 INDIA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 80

TABLE 97 INDIA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 98 SOUTH KOREA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 99 SOUTH KOREA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 81

TABLE 100 SOUTH KOREA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 81

TABLE 101 SOUTH KOREA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 81

TABLE 102 REST OF ASIA-PACIFIC: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 103 REST OF ASIA-PACIFIC: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 82

TABLE 104 REST OF ASIA-PACIFIC: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 83

TABLE 105 REST OF ASIA-PACIFIC: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 83

TABLE 106 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2020–2027 (USD MILLION) 84

TABLE 107 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 108 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 85

TABLE 109 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 85

TABLE 110 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 86

TABLE 111 MIDDLE EAST: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 112 MIDDLE EAST: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 87

TABLE 113 MIDDLE EAST: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 87

TABLE 114 MIDDLE EAST: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 87

TABLE 115 AFRICA: ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 116 AFRICA: ALS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 117 AFRICA: ALS MARKET FOR MEDICATION, BY DRUG, 2020–2027 (USD MILLION) 89

TABLE 118 AFRICA: ALS MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 119 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MAJOR PLAYER RANKING, 2020 91


14 List of Figures

FIGURE 1 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET: MARKET STRUCTURE 18

FIGURE 2 RESEARCH PROCESS OF MRFR 20

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 23

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 25

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 29

FIGURE 6 VALUE CHAIN: GLOBAL AMYOTROPHIC LATERAL SCLEROSIS MARKET 31

FIGURE 7 GLOBAL ALS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 34

FIGURE 8 GLOBAL ALS MARKET, BY TREATMENT, 2020 AND 2027 (USD MILLION) 37

FIGURE 9 GLOBAL ALS MARKET, BY END USER, 2020 AND 2027 (USD MILLION) 42

FIGURE 10 GLOBAL ALS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 46

FIGURE 11 AMERICAS: ALS MARKET, BY REGION, 2020 (%) 47

FIGURE 12 NORTH AMERICA: ALS MARKET, BY COUNTRY, 2020 (%) 49

FIGURE 13 EUROPE: ALS MARKET, BY REGION, 2020 (%) 56

FIGURE 14 WESTERN EUROPE: ALS MARKET, BY COUNTRY, 2020 (%) 58

FIGURE 15 ASIA-PACIFIC: ALS MARKET, BY COUNTRY, 2020 (%) 72

FIGURE 16 AFRICA: ALSMIDDLE EAST & AFRICA: ALS MARKET, BY REGION, 2020 (%) 84

筋萎縮性側索硬化症市場

筋萎縮性側索硬化症の市場はCAGR 6.1%で、2030年までに772.35万ドルで急成長する

セグメンテーション

タイプ別 Familial Als
By Treatment Medication Physical Therapy Speech Therapy
By Diagnosis Laboratory Tests Imaging Tests
By End User Hospitals Specialty Centers

キープレーヤー

  • Sun Pharmaceutical (India)
  • Mitsubishi Tanabe Pharma America (U.S.)
  • Biogen (U.S.)
  • Sanofi (France)
  • Mylan N.V. (U.S.)
  • Covis Pharma (Switzerland)
  • Ionis Pharmaceutical (U.S.)
  • ITF Pharma (U.S.)
  • Ascend Pharmaceuticals LLC (U.S.)
  • Apotex Inc. (Canada)

運転手

  • Rise in the awareness about the disease among patients
  • Rise in the geriatric population
Speak to Analyst Request a Free Sample

筋萎縮性側索硬化症市場の概要


世界の筋萎縮性側索硬化症市場は、予測期間中に7.89%のCAGRで成長して8億4,160万米ドルに達すると予想されています。2017年の筋萎縮性側索硬化症市場には、合計5億2600万米ドルが費やされました。まれな神経疾患のグループには、筋萎縮性側索硬化症(ALS)が含まれます。脳と脊髄のニューロンは、この神経変性疾患によって深刻な影響を受けます。これらの障害は体内の随意筋肉に影響を及ぼし、運動ニューロン障害とも呼ばれます。ALS患者は、筋肉のけいれんや筋肉の収縮を経験することがあります。筋萎縮性側索硬化症の市場は、高齢者の人口の増加だけでなく、病気の発生率や意識の増加などの要因により成長すると予想されます。


座りがちなライフスタイルに加えて、肥満などの他の要因が市場の成長を促進し、ALSを発症するリスクを高めています。さらに、高齢者の増加は市場の成長を実証し、対症療法と標的治療の需要を生み出しています。


ただし、予測期間中、ALS処理は高すぎて市場を後押しできない可能性があります。


COVID-19筋萎縮性側索硬化症市場の分析


ALS治療業界は、Covid19の発生により、秋以降、信じられないほど成長すると予想されています。このパンデミックの中で、メーカーは持続可能性と業界での地位を維持するための重要な戦略の適用により重点を置いています。筋萎縮性側索硬化症の市場のプレーヤーは、このレポートの情報を使用して、このパンデミックが業界に与える影響に対処できます。


筋萎縮性側索硬化症の市場動態


筋萎縮性平行硬化症感染症の優位性が高まるにつれて、筋萎縮性側索硬化症治療市場の発展に依存しています。発展途上の多くのアメリカ人が筋萎縮性側索硬化症を患っており、疾病管理予防センター(CDC)によると、毎年約5,000人の個人で分析されています。筋萎縮性側索硬化症は、世界中の10万人のうち2〜5人に影響を及ぼします。さらに、老人人口の拡大と不活発な生活様式への傾向は、治療法の選択への関心を高めています。同様に、市場は数字の時間枠で増加するはずです。治療の多大な費用、ALDに対する注意力の低下、治療の選択の制限など、推定期間中に市場を妨げる可能性のあるいくつかの要因があります。


テクノロジー分析


イノベーションの進歩と高齢者の増加は、市場の発展を牽引する主な考慮事項です。さらに、追加の現金の調達と研究開発演習の進行により、2020年から2025年の期間の筋萎縮性側索硬化症市場に対する一般的な市場の関心がさらに向上します。テクノロジーの進歩と治療におけるマインドフルネスの拡大は、この市場の市場開発を推進するいくつかの要素です。さらに、FDAは同様に、筋萎縮性横型硬化症の市場開発を拡大しているALS大衆の胃を収縮させるために埋め込まれた陰極と電池が利用されるNeurXダイヤフラムペーシングシステムを承認しました。


筋萎縮性側索硬化症市場セグメント分析


3つのタイプがあります, 治療オプション, 筋萎縮性側索硬化症内のエンドユーザーKET。


筋萎縮性側索硬化症の市場は、タイプごとに散発性および家族性に分けられます。予測期間中、市場はSALSとしても知られる散発的なALSによって支配される可能性があります。


筋萎縮性側索硬化症市場は、薬物療法、理学療法、呼吸療法、言語療法などの治療の種類に基づいて分割されています。これらの治療の中で、医薬品は2017年に最大の市場シェアを占めました。


筋萎縮性側索硬化症市場のエンドユーザーセグメントには、病院、専門センター、研究および学術機関などが含まれます。病院は、この見出しの下で最大のセグメントを構成します。


次のカテゴリによると、世界の筋萎縮性側索硬化症市場を簡単に理解できます。


タイプ:



  • 散発的な ALS (SALS)

  • 家族性ALS (FALS)


治療:



  • 投薬

  • 理学療法

  • 呼吸器療法

  • スピーチセラピー

  • その他


エンドユーザー:



  • 病院

  • 専門センター

  • 研究および学術機関

  • その他


地域:



  • 北米


    • 米国

    • カナダ


  • ヨーロッパ


    • ドイツ

    • フランス

    • 英国

    • イタリア

    • スペイン

    • Report Attribute/Metric Details   Market Size   2023: USD 841.6 million   CAGR   2018-2023: 7.89%   Base Year   2019   Forecast Period   2027   Historical Data   2018   Forecast Units   Value (USD Million)   Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends   Segments Covered   Type, Treatment and End-User   Geographies Covered   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends   Key Vendors   Sun Pharmaceutical (India), Mitsubishi Tanabe Pharma America (U.S.), Biogen (U.S.), Sanofi (France), Mylan N.V. (U.S.), Covis Pharma (Switzerland), Ionis Pharmaceutical (U.S.), ITF Pharma (U.S.), Ascend Pharmaceuticals LLC (U.S.), Apotex Inc. (Canada)   Key Market Opportunities   Developing healthcare infrastructure   Key Market Drivers

    • Rise in the awareness about the disease among patients
    • Rise in the geriatric population


    • Speak to Analyst Ask for Customization

      Frequently Asked Questions (FAQ) :

      The treatments included in Amyotrophic Lateral Sclerosis Market are medication, physical therapy, respiratory therapy, speech therapy.

      Various tests included in the ALS Market are Laboratory Tests, Imaging Tests and Others

      Hindering factor of the Amyotrophic Lateral Sclerosis Market would be its high treatment cost.

      Amyotrophic Lateral Sclerosis Market would be led by the hospital segment.

      Valuation of the Amyotrophic Lateral Sclerosis Market would be around USD 841.6 million during the forecast period.

      Amyotrophic Lateral Sclerosis Market would grow with a CAGR of 7.89% during the forecast period.

Global Amyotrophic Lateral Sclerosis Treatment Market: Company Landscape


The Global amyotrophic lateral sclerosis treatment market is dominated by several market players such as Mitsubishi Tanabe Pharma America, Sanofi, Mylan N.V., Covis Pharma, and others. The major players in the amyotrophic lateral sclerosis market are opting for new product launches, strategic collaborations, and partnerships to brace their position in the market.


Mitsubishi Tanabe Pharma America is one of the leading players in the amyotrophic lateral sclerosis market. The company is a research-driven pharmaceutical company and offers RADICAVA (Edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS). Radicava is a free radical scavenger and slows the progression of ALS by removing free radicals in the nervous system. The company has successfully integrated small companies through mergers and acquisitions to build a strong supply chain network. High customer satisfaction level, exceptional performance in new markets, and strong brand portfolio add to the company’s competitive advantage.


Sanofi is a key player owing to its product RILUTEK (Riluzole). RILUTEK is available as a capsule-shaped, film-coated tablet for oral administration containing 50 mg of Riluzole. The drug helps to slow down the worsening of this disease and prolong survival. Rilutek (Riluzole) was the first drug approved by the US Food and Drug Administration (FDA), in December 1995, to treat amyotrophic lateral sclerosis (ALS). It was originally developed by a French company, Rhone-Poulenc Rorer and is now marketed by Sanofi. Sanofi employs a strategy of maintaining the quality of products by maximum automation and rising investments on research and development which help the company in maintaining its market position. Additionally, the company is engaged in strategic collaborations which facilitates it to strengthen its position and expand its market presence globally.


Covis Pharma is a renowned company in the amyotrophic lateral sclerosis market. The company operates in various business units and produces branded and generic pharmaceutical products and injectables in cardiovascular, central nervous system, oncology, and acute care markets. In April 2015, the company was acquired by Advanz Pharmaceuticals. The strategy of the company is to expand its generic and branded drugs business, thus bracing its position in the market.


Mylan N.V. accounted is one of the prominent players operating in the global amyotrophic lateral sclerosis treatment market. The company’s global portfolio constitutes more than 7,500 marketed generic and branded generic, brand names, and OTC products around the world covering a wide range of therapeutic areas. The company is engaged in strategic collaborations and mergers which helps the company to hold its market position.


Sun Pharmaceutical Industries Ltd delivers high quality and reasonable medicines trusted by customers in over 150 countries globally. The company aims to provide high-quality products to expand its generic business, and thus strengthen its position in the market.


One of the prominent players in the market is ITF Pharma. The company is engaged in the development and sale of branded prescription and non-prescription pharmaceutical products. In September 2018, ITF Pharma announced the FDA approval of tiglutik (Riluzole) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).


Other key companies in the amyotrophic lateral sclerosis treatment market are Ascend Pharmaceuticals LLC and Apotex Inc.